VG1196

VG1196 is an experimental peptide being investigated by VG Life Sciences as part of a series of novel immunomodulatory peptides, alongside analogs VG1197 and VG1198, designed based on internal medicinal chemistry optimization to pursue a more potent compound for autoimmune and inflammatory indications. While detailed structure, target, and pharmacology have not been publicly disclosed, VG1196 derives from VG Life Sciences’ platform focused on modifying immune responses, suggesting it is intended to alter pathogenic immune signaling pathways implicated in chronic inflammatory disease rather than act as a conventional small-molecule inhibitor or broad immunosuppressant.[7]